Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial

Aim: The aim of this work was to study the factors affecting the stability of working patients in antimuscarinic (AM) drug treatment. Background: The prevalence of urge urinary incontinence (UUI) is an average of between 8.2% and 16.0% of the population. UUI is a condition that adversely affects the...

Full description

Bibliographic Details
Main Authors: Kirill Vladimirovich Kosilov, Sergey Loparev, Irina Kuzina, Olga Shakirova, Nataliya Zhuravskaya, Alexandra Lobodenko
Format: Article
Language:English
Published: SAGE Publishing 2016-08-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/1756287216652030
id doaj-0eb05a49b1e44f1fa52669f8ae20c4c8
record_format Article
spelling doaj-0eb05a49b1e44f1fa52669f8ae20c4c82020-11-25T04:10:41ZengSAGE PublishingTherapeutic Advances in Urology1756-28721756-28802016-08-01810.1177/1756287216652030Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trialKirill Vladimirovich KosilovSergey LoparevIrina KuzinaOlga ShakirovaNataliya ZhuravskayaAlexandra LobodenkoAim: The aim of this work was to study the factors affecting the stability of working patients in antimuscarinic (AM) drug treatment. Background: The prevalence of urge urinary incontinence (UUI) is an average of between 8.2% and 16.0% of the population. UUI is a condition that adversely affects the health-related quality of life. The first-line therapy in managing UUI is AM treatment. Methods: In 1006 patients between 18 and 60 years old (627 women, 379 men, mean age 69.4) who received AM treatment for one year, the possible demographic, socioeconomic and health factors influencing compliance were studied. Also, the functional state of the lower urinary tract (LUT) was studied in this randomized, prospective survey. The study instruments were the documents of employers, tax offices, outpatient records, OABq-SF (overactive bladder - short form) questionnaires, MOS SF-36 (Medical Outcomes Study short form-36), voiding charts, and uroflowmetry data. Results: The compliance to AM treatment within 6 months was retained in 49.5% patients; during the year, in 32.3% of patients. The average time for reaching the 30-day break in taking trospium was 194 days. In the course of the experiment it was revealed that compliance to AM treatment was significantly higher in patients taking solifenacin and trospium in high dosages ( p ⩽ 0.01, p ⩽ 0.05), suffering from severe symptoms of urgency ( p ⩽ 0.01), and having a low level of side effects ( p ⩽ 0.01). A satisfactory level of compliance is characteristic of patients with a high level of monthly and annual income ( p ⩽ 0.01, p ⩽ 0.01), a low percentage of expenses to AM ( p ⩽ 0.05), and rarely changing employers ( p ⩽ 0.05). In addition, the compliance to treatment is higher in older adults ( p ⩽ 0.05), living in the urban district ( p ⩽ 0.01), and working in educational ( p ⩽ 0.05) and health ( p ⩽ 0.01) institutions, having a high level of the indices of Social Functioning ( p ⩽ 0.05), Role-Emotional ( p ⩽ 0.05), and Mental Health ( p ⩽ 0.01). Conclusion: As a result of this study, under the control of the objective functional state of LUT, the influence of various factors on the patients’ stability in the treatment with AM drugs was revealed.https://doi.org/10.1177/1756287216652030
collection DOAJ
language English
format Article
sources DOAJ
author Kirill Vladimirovich Kosilov
Sergey Loparev
Irina Kuzina
Olga Shakirova
Nataliya Zhuravskaya
Alexandra Lobodenko
spellingShingle Kirill Vladimirovich Kosilov
Sergey Loparev
Irina Kuzina
Olga Shakirova
Nataliya Zhuravskaya
Alexandra Lobodenko
Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
Therapeutic Advances in Urology
author_facet Kirill Vladimirovich Kosilov
Sergey Loparev
Irina Kuzina
Olga Shakirova
Nataliya Zhuravskaya
Alexandra Lobodenko
author_sort Kirill Vladimirovich Kosilov
title Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
title_short Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
title_full Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
title_fullStr Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
title_full_unstemmed Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
title_sort treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
publisher SAGE Publishing
series Therapeutic Advances in Urology
issn 1756-2872
1756-2880
publishDate 2016-08-01
description Aim: The aim of this work was to study the factors affecting the stability of working patients in antimuscarinic (AM) drug treatment. Background: The prevalence of urge urinary incontinence (UUI) is an average of between 8.2% and 16.0% of the population. UUI is a condition that adversely affects the health-related quality of life. The first-line therapy in managing UUI is AM treatment. Methods: In 1006 patients between 18 and 60 years old (627 women, 379 men, mean age 69.4) who received AM treatment for one year, the possible demographic, socioeconomic and health factors influencing compliance were studied. Also, the functional state of the lower urinary tract (LUT) was studied in this randomized, prospective survey. The study instruments were the documents of employers, tax offices, outpatient records, OABq-SF (overactive bladder - short form) questionnaires, MOS SF-36 (Medical Outcomes Study short form-36), voiding charts, and uroflowmetry data. Results: The compliance to AM treatment within 6 months was retained in 49.5% patients; during the year, in 32.3% of patients. The average time for reaching the 30-day break in taking trospium was 194 days. In the course of the experiment it was revealed that compliance to AM treatment was significantly higher in patients taking solifenacin and trospium in high dosages ( p ⩽ 0.01, p ⩽ 0.05), suffering from severe symptoms of urgency ( p ⩽ 0.01), and having a low level of side effects ( p ⩽ 0.01). A satisfactory level of compliance is characteristic of patients with a high level of monthly and annual income ( p ⩽ 0.01, p ⩽ 0.01), a low percentage of expenses to AM ( p ⩽ 0.05), and rarely changing employers ( p ⩽ 0.05). In addition, the compliance to treatment is higher in older adults ( p ⩽ 0.05), living in the urban district ( p ⩽ 0.01), and working in educational ( p ⩽ 0.05) and health ( p ⩽ 0.01) institutions, having a high level of the indices of Social Functioning ( p ⩽ 0.05), Role-Emotional ( p ⩽ 0.05), and Mental Health ( p ⩽ 0.01). Conclusion: As a result of this study, under the control of the objective functional state of LUT, the influence of various factors on the patients’ stability in the treatment with AM drugs was revealed.
url https://doi.org/10.1177/1756287216652030
work_keys_str_mv AT kirillvladimirovichkosilov treatmentcomplianceofworkingpersonstohighdoseantimuscarinictherapiesarandomizedtrial
AT sergeyloparev treatmentcomplianceofworkingpersonstohighdoseantimuscarinictherapiesarandomizedtrial
AT irinakuzina treatmentcomplianceofworkingpersonstohighdoseantimuscarinictherapiesarandomizedtrial
AT olgashakirova treatmentcomplianceofworkingpersonstohighdoseantimuscarinictherapiesarandomizedtrial
AT nataliyazhuravskaya treatmentcomplianceofworkingpersonstohighdoseantimuscarinictherapiesarandomizedtrial
AT alexandralobodenko treatmentcomplianceofworkingpersonstohighdoseantimuscarinictherapiesarandomizedtrial
_version_ 1724419681424506880